Keywords
Asthma ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

461 Search results.

A Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of CAT-354 - Eligibility

- 5/22/15 - 1 form, 2 itemgroups, 27 items, 2 languages
Itemgroups: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00640016

Eligibility Difficult Asthma NCT01862289

- 11/23/19 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Prevalence of Hyperventilation Syndrome in Difficult Asthma; ODM derived from: https://clinicaltrials.gov/show/NCT01862289

A Parallel Group Study of Fluticasone Furoate/Vilanterol in Subjects with Asthma - 106837 - Concomitant Medications Form

- 10/30/19 - 1 form, 1 itemgroup, 22 items, 1 language
Itemgroup: Concomitant Medication Details
Study ID: 106837 Clinical Study ID: HZA106837 Study Title: A Long-Term, Randomized, Double-Blind, Parallel Group Study of Fluticasone Furoate/GW642444 Inhalation Powder Once-Daily and Fluticasone Furoate Inhalation Powder Once-Daily in Subjects with Asthma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01086384 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fluticasone furoate/vilanterol Trade Name: Relvar Study Indication: Asthma

Eligibility Bronchial Asthma With eNO-levels Greater Than 30 ppB NCT01543516

- 10/21/19 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Cell Distribution in Induced Sputum in Patients With Asthma; ODM derived from: https://clinicaltrials.gov/show/NCT01543516

Eligibility Bronchial Asthma NCT01618929

- 10/21/19 - 1 form, 2 itemgroups, 20 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Effects of Montelukast in Asthmatic Children With and Without Food Allergy; ODM derived from: https://clinicaltrials.gov/show/NCT01618929

Eligibility Bronchial Asthma NCT01455194

- 10/21/19 - 1 form, 2 itemgroups, 9 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Effect of High Dose Ciclesonide on Asthma Control; ODM derived from: https://clinicaltrials.gov/show/NCT01455194

Eligibility Bronchial Asthma NCT01414868

- 10/21/19 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Leukotriene D4 Bronchial Provocation Test (LTD4-BPT) as an Indicator for the Use of Leukotriene Receptor Antagonist (LTRA); ODM derived from: https://clinicaltrials.gov/show/NCT01414868

Eligibility Bronchial Asthma NCT01386151

- 10/21/19 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study to Assess Safety and Efficacy of a Novel Treatment, Keratinocyte Growth Factor (KGF), in Asthmatic Patients; ODM derived from: https://clinicaltrials.gov/show/NCT01386151

Eligibility Bronchial Asthma NCT01113437

- 10/21/19 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Criteria, Exclusion Criteria
Omalizumab in Non-atopic Asthma; ODM derived from: https://clinicaltrials.gov/show/NCT01113437

Eligibility Bronchial Asthma NCT01759472

- 10/7/19 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Effect Study of Montelukast to Treat Asthma Detected by LTD4 Bronchial Effect Study of Montelukast to Treat Asthma Detected by LTD4 Bronchial Provocation Test; ODM derived from: https://clinicaltrials.gov/show/NCT01759472

Magnesium Sulfate in Bronchial Asthma NCT02455687 - Eligibility Criteria

- 6/15/19 - 1 form, 2 itemgroups, 20 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Two Doses of the Intravenous Magnesium Sulfate Versus the Standard Single Dose ,With/ Without the Nebulized Budesonide For the Management of the Severe Asthma Exacerbation in the Emergency Room; A Randomized Controlled Trial.; ODM derived from: https://clinicaltrials.gov/show/NCT02455687 Many studies have worked on the efficacy and safety of Intravenous magnesium sulfate and inhaled steroids beside the standard treatment for patients with severe asthma attacks. Investigators hypothesize that, two doses if intravenous magnesium sulfate with or without inhaled budesonide, would make the stay at the Pediatric emergency center (PEC) lesser,and decrease the need of being admitted to Pediatric Intensive Care Unit (PICU) for children with severe asthma attacks,compared to single dose of magnesium sulfate with or without inhaled budesonide.

Eligibility Prednisone Dependent Asthma NCT02049294

- 6/14/19 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study of the Prednisone Sparing Effect of Xolair (Omalizumab) in Patients With Prednisone-dependent Asthma With Eosinophilic Bronchitis; ODM derived from: https://clinicaltrials.gov/show/NCT02049294